Chinese expert consensus on diagnosis and treatment of radiation pneumonitis

Radiotherapy is one of the main tumor treatment modalities that provides great survival benefits to patients with cancer. However, it is important to pay attention to the occurrence of adverse events after radiotherapy and take early measures. Radiation pneumonitis (RP) is a major adverse response in patients with cancer receiving thoracic radiotherapy, and it affects the quality of life and survival of patients. We analyzed the latest evidence on RP, and summarized research developments on the pathophysiological mechanism, risk factors, clinical manifestations, diagnosis and differential diagnosis, classification, treatment, and prognosis to form a consensus. With the development of comprehensive treatments, including immunotherapy, the diagnosis and identification of RP has become more complex, requiring multidisciplinary discussion and decision‐making. In the future, it is critical to explore more effective treatments, various risk factors, and precautions for RP.

[1]  Yi-long Wu,et al.  Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. , 2022, The Lancet. Oncology.

[2]  Jeong Yun Jang,et al.  Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study , 2021, Radiation Oncology.

[3]  Keunchil Park,et al.  Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer , 2021, JAMA oncology.

[4]  Jinming Yu,et al.  Computed tomography-based delta-radiomics analysis for discriminating radiation pneumonitis in patients with esophageal cancer after radiation therapy. , 2021, International journal of radiation oncology, biology, physics.

[5]  E. Hau,et al.  A systematic review and meta-analysis of treatment-related toxicities of curative and palliative radiation therapy in non-small cell lung cancer , 2021, Scientific Reports.

[6]  Hongyu Wu,et al.  Risk factors for radiation pneumonitis in lung cancer patients with subclinical interstitial lung disease after thoracic radiation therapy , 2021, Radiation oncology.

[7]  D. Lynch,et al.  Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. , 2021, Radiology.

[8]  D. Lynch,et al.  Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. , 2021, Chest.

[9]  O. Arrieta,et al.  Radiation-induced lung injury: current evidence , 2021, BMC Pulmonary Medicine.

[10]  U. Dafni,et al.  Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (ETOP 6-14). , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  Jinming Yu,et al.  Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications , 2020, BMC Medicine.

[12]  Q. Lin,et al.  Stereotactic body radiotherapy for early stage non-small cell lung cancer in patients with subclinical interstitial lung disease , 2020, Translational lung cancer research.

[13]  A. Sheshadri,et al.  Immune-Related Adverse Events: Pneumonitis , 2020, Advances in experimental medicine and biology.

[14]  Ying Zhou,et al.  Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters , 2019, Strahlentherapie und Onkologie.

[15]  Hsuan-Fu Kuo,et al.  Azithromycin suppresses Th1- and Th2-related chemokines IP-10/MDC in human monocytic cell line. , 2019, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[16]  V. Jendrossek,et al.  The CD73/Ado System—A New Player in RT Induced Adverse Late Effects , 2019, Cancers.

[17]  J. Cadranel,et al.  Dramatic Radiation Recall Pneumonitis Induced by Osimertinib after Palliative Thoracic Radiotherapy for Lung Cancer. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  E. Weiss,et al.  Fatal Radiation Pneumonitis: Literature Review and Case Series , 2019, Advances in radiation oncology.

[19]  Jun Liang,et al.  Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy , 2019, BMC Cancer.

[20]  S. Kroeze,et al.  Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries , 2019, Strahlentherapie und Onkologie.

[21]  C. Lin,et al.  Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  R. Sullivan,et al.  Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.

[23]  Geoffrey D. Hugo,et al.  Diabetes mellitus and radiation induced lung injury after thoracic stereotactic body radiotherapy. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  Jinming Yu,et al.  Abscopal effect of radiotherapy combined with immune checkpoint inhibitors , 2018, Journal of Hematology & Oncology.

[25]  R. Mohan,et al.  Clinical and Dosimetric Factors Predicting Grade ≥2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma. , 2018, International journal of radiation oncology, biology, physics.

[26]  Tinsu Pan,et al.  Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study , 2018, Quality of Life Research.

[27]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[28]  Wei Chen,et al.  Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  N. Viñolas,et al.  Feasibility, tolerability, and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small-cell lung cancer: a Phase II trial , 2016, OncoTargets and therapy.

[30]  W. Mao,et al.  Analysis of Clinical and Dosimetric Factors Influencing Radiation-Induced Lung Injury in Patients with Lung Cancer , 2015, Journal of Cancer.

[31]  Shulian Wang,et al.  Nondosimetric risk factors for radiation-induced lung toxicity. , 2015, Seminars in radiation oncology.

[32]  Yang Yao,et al.  Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials , 2015, Journal of chemotherapy.

[33]  Randall K Ten Haken,et al.  Effect of normal lung definition on lung dosimetry and lung toxicity prediction in radiation therapy treatment planning. , 2013, International journal of radiation oncology, biology, physics.

[34]  Jun Liang,et al.  Management and outcome of symptomatic radiation induced lung injury in non-small cell lung cancer , 2013 .

[35]  Jae-Sung Kim,et al.  Predictors of radiation pneumonitis and pulmonary function changes after concurrent chemoradiotherapy of non-small cell lung cancer , 2013, Radiation oncology journal.

[36]  Tae Hyun Kim,et al.  Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. , 2013, International journal of radiation oncology, biology, physics.

[37]  I. Vogelius,et al.  A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis , 2012, Acta oncologica.

[38]  E. Gore,et al.  Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy. , 2012, International journal of radiation oncology, biology, physics.

[39]  Lujun Zhao,et al.  Risk factors for radiation-induced lung toxicity in patients with non-small cell lung cancer who received postoperative radiation therapy. , 2012, Lung cancer.

[40]  Joseph O. Deasy,et al.  Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Based Hybrid Patient and Physician Questionnaire for Head and Neck (HN) Radiotherapy Symptom Reporting , 2011 .

[41]  Myungsoo Kim,et al.  Factors predicting radiation pneumonitis in locally advanced non-small cell lung cancer , 2011, Radiation oncology journal.

[42]  Hubert Thierens,et al.  Predicting risk of radiation-induced lung injury. , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[43]  R. Komaki,et al.  Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis. , 2007, International journal of radiation oncology, biology, physics.

[44]  Randall K Ten Haken,et al.  Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. , 2006, International journal of radiation oncology, biology, physics.

[45]  A. Sasse,et al.  Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. , 2006, International journal of radiation oncology, biology, physics.

[46]  Jeffrey Bradley,et al.  Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. , 2005, International journal of radiation oncology, biology, physics.

[47]  Joos V Lebesque,et al.  Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.

[48]  David Pérol,et al.  A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[49]  T. Samulski,et al.  ASSESSMENT OF THE PROTECTIVE EFFECT OF AMIFOSTINE ON RADIATION-INDUCED PULMONARY TOXICITY , 2002, Experimental lung research.

[50]  T. Raffin,et al.  Pulmonary radiation injury. , 1997, Chest.

[51]  D. Gandara,et al.  Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  A. Arden,et al.  Development of radiation pneumonitis. Time and dose factors. , 1962, Archives of pathology.

[53]  V. Kouloulias,et al.  Suggestion for a new grading scale for radiation induced pneumonitis based on radiological findings of computerized tomography: correlation with clinical and radiotherapeutic parameters in lung cancer patients. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[54]  B. Ozturk,et al.  Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. , 2004, International journal of radiation oncology, biology, physics.

[55]  S. Johnson Guidelines for patients. , 1991, Journal of obstetric, gynecologic, and neonatal nursing : JOGNN.

[56]  H. Libshitz,et al.  Complications of radiation therapy: the thorax. , 1974, Seminars in roentgenology.